^
Association details:
| Biomarker: | NRAS Q61K |
|---|---|
| Cancer: | Melanoma |
| Drug: | LY3009120 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Excerpt:
Similarly, in NRAS Q61K SKMel-30 melanoma model, LY3009120 at 15 or 30 mg/kg BID showed dose-dependent tumor growth inhibition (Figure 7G). Altogether, these in vivo efficacy studies suggest that LY3009120 is active at inhibiting tumor growth with KRAS or NRAS mutation...Table 1Anti-proliferation Activities of LY3009120, Vemurafenib, and Selumetinib in Melanoma Cells in Soft Agar Assays
DOI:
https://doi.org/10.1016/j.ccell.2015.08.002
